Health Economics›Prostate cancer›Hormonal therapy for metastatic or locally advanced disease

Hormonal therapy for metastatic or locally advanced disease

Prostate cancer · 26 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Flutamide and Leuprolide Variant #01	—	R 254 858	28d	—	69.6 mo	2	R 509 716 PFS proxy	1
Leuprolide monotherapy Variant #01	—	R 253 833	90d	—	—	2	R 507 665 PFS proxy	2
ADT, Darolutamide, Docetaxel Variant #01 Partial	—	R 25 149	21d	—	—	7	R 173 768 PFS proxy	1
Docetaxel, Estramustine, Goserelin Variant #01 Partial	—	R 18 039	90d	—	—	~11	~R 103 691 indirect	—
ADT, Enzalutamide, Talazoparib Variant #01 Partial	—	R 14 528	28d	—	—	2	R 29 057 PFS proxy	2
Goserelin monotherapy Variant #01	—	R 10 511	28d	—	—	~2	~R 18 395 indirect	—
Bicalutamide and Leuprolide Variant #01	—	R 9 531	28d	24.7 mo	70.2 mo	2	R 19 062 PFS proxy	3
Bicalutamide and Goserelin Variant #01	—	R 8 166	84d	—	—	1	R 8 166 PFS proxy	1
Degarelix monotherapy Variant #04	—	R 4 219	84d	—	—	~2	~R 5 907 indirect	—
Flutamide and Goserelin Variant #01	—	R 3 653	28d	—	69.6 mo	2	R 7 306 PFS proxy	1
ADT and Docetaxel Variant #01 Partial	—	R 2 272	21d	—	58.3 mo	9	R 20 450 PFS proxy	4
Triptorelin monotherapy Variant #01	—	R 1 535	28d	—	—	~9	~R 13 818 indirect	—
Bicalutamide monotherapy Variant #01	—	R 1 396	28d	—	—	2	R 2 792 PFS proxy	1
ADT and Apalutamide Variant #01 Partial	—	R 1 206	—	—	73.9 mo	1	R 1 206 PFS proxy	2
Flutamide monotherapy Variant #01	—	R 1 025	28d	—	—	~2	~R 2 051 indirect	—
ADT and Enzalutamide Variant #01 Partial	—	R 519	—	17.6 mo	33.7 mo	1	R 519 PFS proxy	8
ADT and Abiraterone Variant #01 Partial	—	R 369	—	—	76.6 mo	1	R 369 PFS proxy	3
ADT and Flutamide Variant #01 Partial	—	R 37	—	—	—	1	R 37 PFS proxy	1
ADT and Bicalutamide Variant #01 Partial	—	R 17	—	5.8 mo	—	1	R 17 PFS proxy	4
ADT and Nilutamide Variant #01 Partial	—	—	—	—	—	1	—	1
Histrelin monotherapy Variant #01 Partial	—	—	—	—	—	~2	—	—
Intermittent ADT Variant #01 Partial	—	—	240d	—	83.4 mo	2	—	3
Nilutamide and Orchiectomy Variant #01 Partial	—	—	30d	—	—	~2	—	—
Relugolix monotherapy Variant #01 Partial	—	—	336d	—	—	~1	—	—
ADT Variant #01 Partial	—	—	—	—	52.0 mo	1	—	14
Abarelix monotherapy Variant #01 Partial	—	—	30d	—	—	~2	—	—

26 of 26 regimens shown